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Perinatal Development of Conjugative
Enzyme Systems
byGeorge W. Lucier*
The problems and priorities involved in studying the role of conjugagive enzymes in develop-
mental pharmacology are discussed and evaluated. The relative rates of UDP glucuronyltrans-
fererase and P-glucuronidase were studied during perinatal development in hepatic and ex-
trahepatic tissues to determine the net balance of glucuronidation or deglucuronidation at
different developmental stages. In general, deglucuronidation predominated over glucuronida-
tion in fetal tissues whereas the converse was evident in adults. 2,3,7,8-Tetrachlorodibenzo-
p-dioxin ITCDD), an extremely toxic contaminant ofsome organochlorine compounds, was shown
to be a potent inducer of some hepatic and extrahepatic drug-metabolizing enzymes. TCDD, ad-
ministered during gestation, induced the postnatal activities of p-nitrophenol glucuronyltrans-
ferase and benzpyrene hydroxylase in rats. Foster mother experiments revealed that the postnatal
induction was caused primarily by newborn exposure to TCDD in the mother's milk. Tissue dis-
tribution experiments with TCDD-'4C confirmed these findings. Although TCDD induced non-
steroid glucuronidation, no significant effects were evident on the postnatal development of
steroid glucuronidation. The synthetic estrogen diethylstilbestrol IDESIis metabolized primarily
by glucuronidation. The postnatal development of DESglucuronidation, like the steroid pathway,
was not affected by gestational TCDD treatment. The fetal distribution of DES and DES-glucu-
ronide, at different stages of development, correlated well with the perinatal development of
steroid glucuronyltransferase activity.
Introduction
Many of the inherent problems in studying
perinatal drug metabolism have been described
previously (1), and in general these apply to
development aspects of conjugative enzymes as
well.
On simplification, and depending on chemical
structure, the drug biotransformation process
may be separated into two parts: first an oxi-
dative reaction, such as hydroxylation, results in
the formation of a free hydroxyl group; this is
then rapidly conjugated with glucuronic acid, sul-
fate, or another conjugate (2 a). This series of
reactions renders the molecule more polar and
generally more excretable. Although the con-
jugative enzymes do not appear to be as complex
as the mfo systems, there are many complicating
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factors. For example, deconjugative reactions
such as P-glucuronidase (3G) and aryl sulfatase
perform the opposite reaction to form a less polar
compound; liberating the free aglycone in the
case of PG (3). Like the mixed function oxidase
(mfo) enzymes, many of the conjugative proc-
esses also play important roles in steroid
metabolism as well as drug metabolism (4).
Glucuronides are often considered end products
of metabolism, whereas sulfates play an integral
role in steroidogenesis (5), an area of obvious con-
cern to the developmental toxicologist.
Some ofthe conjugative enzymes, most notable
uridinediphosphoglucuronyltransferase, (UDP
glucuronyltransferase, UDPGT), are microsomal
and inducible by many of the same compounds
that induce mfo enzymes, such as TCDD and
phenobarbital (6-9). However, these enzymes are
not P-450-dependent and some, such as the sul-
fotransferases, are located in the soluble fraction
ofmammalian cells (10).
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portant objectives in studying the perinatal de-
velopment of conjugative enzymes and this will
be followed by recent research data related to
these objectives. Most of the examples will in-
volve UDPGT because of the available literature
in developing systems, although other enzyme
systems are also important. The sulfotrans-
ferases have been given relatively little attention
because of the difficulty in obtaining sufficient
quantities of phosphoadenosine phosphosulfate,
the cofactor in sulfate transfer. This is now
becoming commercially available, and sulfation
will become a more easily studied process. N-
Acetyltransferase (NAT) functions in metabolism
of some endogenous amines such as serotonin and
the deactivation of many drugs (11). Glycine con-
jugation is involved in the metabolism of some
carbamate pesticides and functions in the heme
biosynthetic pathway (2b).
Perinatal Development of Conjugative Enzyme
Systems: Objectives
Characterize the Perinatal Development Patterns
of Conjugative Enzyme Systems in Experimental
Animals
Like other biochemical processes, the activity
of conjugative enzymes can vary tremendously
depending on age, species, strain, time of day,
and with exposure to other xenoboitics. In re-
gards to mixed function oxidase activity, human
fetal microsomes have significant activity, but ex-
perimental animals, at least noninduced animals,
have low activities (12,13). In contrast, UDPGT
has low activity in human fetal and kidney
microsomes, whereas activity is quite high in
the livers of the late fetuses of many experi-
mental animals (8,14). These data constitute
serious drawbacks in attempts to extrapolate
data from experimental animals to the human
condition. The low activity of most enzymes in
fetal tissues often makes their measurement dif-
ficult. However the recent development of sensi-
tive radiochemical procedures should help alle-
viate this problem (15,16).
Investigate Developmental Patterns of Steroid
Conjugative Enzymes as Well as Nonsteroid
Pathways
As mentioned previously, the conjugative
pathways play an important role in steroid me-
tabolism as well as drug metabolism; especially
sulfation and glucuronidation. There is con-
siderable evidence supporting the idea that a
different set of UDPGT conjugates steroids than
nonsteroids (8,17-19). Although the evidence is
not entirely conclusive, it is reasonable to assume
that the developmental patterns, tissue distribu-
tions, and responses to inducing agents might be
different for steroid conjugations compared to
nonsteroid pathways.
Determine Developmental Patterns in Extrahe-
patic as Well as Hepatic Tissues
In recent years, increasing attention has been
placed on the role ofextrahepatic drug-metaboliz-
ing enzymes in fetuses as well as adults (20,21).
The fetus has to be considered differently from
adults, since foreign chemicals reach the fetus via
the placenta whereas several routes of exposure
are possible after birth. Also, fetal biotransfor-
mation capabilities differ markedly from those of
mature animals (22). Of course, the amount of
parent compound or metabolites entering the
fetus will vary depending on the mode of mater-
nal exposure. It is important to determine the
onset of conjugative activity in specific fetal
tissues. This information should provide insight
into how the fetus independently handles foreign
chemicals at different developmental stages. We
should also attempt to correlate these factors
with susceptibility to transplacental toxicants.
Quantify the Balance between Conjugative and
Deconjugative Processes in Different Tissues at
Different Developmental Stages
The net conjugation and fate of conjugates in a
particular tissue depends on a number of factors,
including deconjugation, other metabolisms,
transport, and binding to specific and nonspecific
sites. The ability of a xenobiotic to elicit a phys-
iological response depends on the binding proper-
ties of that chemical and how subsequent metabo-
lism affects binding properties. Therefore, there
is a strong rationale to study the ontogeny of
drug-receptor interactions as well as the on-
togeny of drug metabolism. Bearing on this prob-
lem is the potential for xenobiotics and their
metabolites to interfere with normal hormone-
receptor interactions.
The net conjugation in vitro can be determined
by measuring separately, conjugation and decon-
jugation. However, this approach is fraught with
many problems, and it is difficult to extrapolate
to the in vivo condition. There are several
reasons for this. First, the pH optima for conju-
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than for deconjugation reactions. For example,
PG is most active at pH 4.5 (3) and UDPGT at pH
7.5 (7), with very little cross activity at the
respective pH values. Of course, the possibility
exists that there are microspheres of low pH in
vivo allowing for PG activity. Another com-
plicating factor involves the necessity to activate
UDPGT by adding microsomal membrane per-
turbing agents to in vitro tissue preparations
(23-26). The in vitro incubation conditions that
most adequately reflect in vivo activities is a
question which has not been adequately resolved.
In addition, in vitro activation of fetal tissues
might differ qualitatively or quantitatively from
that of adult tissues, depending on the morpho-
logical localization of enzyme on the endoplasmic
reticulum.
Conjugation and deconjugation reactions are of
particular interest in the placenta, since the
fetal-maternal transfer of some steroids is regu-
lated by the net deconjugation rates (5). This is
particually true for the steroid sulfates.
Determine Alteration of Perinatal Enzyme Devel-
opment by Gestational Exposures to Environ-
mental Chemicals
It is well known that some conjugative en-
zymes are induced by certain xenobiotics (6-9).
We feel that is is important to determine how the
perinatal development of steroid and nonsteroid
biotransformation activities might be changed by
gestational or newborn exposure to environmen-
tal contaminants. We should also determine
which tissues are most sensitive to perinatal in-
duction or suppression.
Correlate Developmental Changes in Enzyme Ac-
tivity with Changes in Toxicity and Fetal Phar-
macology ofForeign Compounds
Scientists working in the area of perinatal
pharmacology should attempt to correlate devel-
opmental enzyme fluctuations with the pharma-
cology of foreign compounds. We should also use
pharmacokinetics as a tool to ascertain periods of
fetal susceptibility totransplacentaltoxicology.
Do Changes in Developmental Patterns of Conju-
gative Enzymes Provide Reliable Indicators of
Developmental and Reproductive Toxicity?
An area of recent concern to the NIEHS in-
volves the identification of biochemical indicators
that precede or accompany developmental toxici-
ty. There is some evidence that the developmen-
tal pattern of conjugative enzyme pathways could
relfect impending toxicity. This area is covered in
detail in a separate article (27).
What are the Factors that Regulate Onset of
Conjugative Activity in the Fetus orNewborn?
This objective is of great importance to devel-
opmental toxicologists in relation to the factors
that could delay or prematurely initiate onset of
enzyme activity. Dutton's group in England has
done considerable and elegant work on this sub-
ject (19). They have used chick embryo liver
cultures to study the developmental induction of
glucuronyltransferase activity. Enzyme activity
increases markedly in culture and actually ex-
ceeds that found normally in adult liver. Figure 1
illustrates the glucuronidation of a phenolic com-
pound catalyzed by UDPGT. This process re-
quires UDPGA as the cofactor and glucuronic
acid donor. UDPGA synthesis is catalyzed by an
NAD+-dependent UDPG dehydrogenase and is
degraded by a nucleotide pyrophosphatase. How-
ever fetal UDPGA condentration is not the pri-
mary factor in regulating the onset of glucuroni-
dation activity. The glucuronide product can also
be degraded by PG, and high levels of this
hydrolytic activity might be responsible for low
fetal glucuronidation rates. However, this was
also shown not to be the case, since PG inhibitors
did not alter glucuronidation rates, and PG had
only negligible activity at the pH used to measure
glucuronidation. THe conclusion was that devel-
opmental onset of glucuronidation appears to be
regulated by increased amounts of UDPGT
(19,28). This idea was further reinforced by the
ability of protein synthesis inhibitors to prevent
the developmental onset of activity (29). How-
ever, the situation is complicated by the fact that
OH O-Glucuronide
UDP
tN Glucuronyltransferase
UDP Glucuronic acid
3-glucuronidase
OH
FIGURE 1. Schematic representation ofUDPGT and
PG activity.
December 1976 27yolk added to the tissue culture delays the devel-
opment ofglucuronyltransferase (19).
Perinatal Development of Glucuronyltransferase
and P-Glucuronidase
The perinatal development of microsomal
(-glucuronidase (PG) and UDP glucuronyltrans-
ferase (UDPGT) was investigated in rabbits,
rats, and guinea pigs. Substrates used in these
studies were p-nitrophenol (PNP) and p-nitro-
phenyl P-D-glucuronide. Results for guinea pig
tissues are illustrated on Figures 2-6. PG is loca-
ted in both microsomal and lysosomal fractions.
The data illustrated in Figures 2-6 represent the
developmental patterns for PG only in micro-
somes, since the patterns were similar for both
microsomes and lysosomes. In liver, glucuronida-
tion was first evident at day 38 of gestation, and
activity gradually increased. The increase was
dramatic near birth, so that for the first week
after birth enzyme activity exceeded adult levels.
IG activity developed prior to UDPGT in liver
and deconjugation exceeded conjugation until
day 54 of gestation. Glucuronidation predom-
inated at all subsequent developmental stages;
the difference reaching a maximum of sevenfold
by one week after birth and threefold in adults. In
general, rats exhibited similar developmental
patterns as guinea pigs but rabbits were dif-
ferent, in that no developmental peak in UDPGT
activity about the time of birth was evident.
Guinea pig lung exhibited a different develop-
mental pattern than liver. UDPGT was not detec-
table until just after birth, and adult activities
were low; being approximately 1 nmole/min/mg
protein, compared to approximately 50 in liver.
fG was active in fetal lung and activities in-
creased sharply about the time of birth. Deglu-
curonidation exceeded glucuronidation at all
developmental stages tested based on specific ac-
tivities. The difference was approximately four-
fold in adults.
Unusual developmental patterns were ob-
served in the intestine with regard to PG. Fetal
activities were extremely high: approximately 50
nmole/min/mg microsomal protein. PG activities
decreased sharply after birth, reaching adult
levels of approximately 5 nm/min/mg by 21 days
after birth. Similar high levels of fetal and new-
born intestinal PG were observed in rabbits and
rats. The importance of PG in fetal and newborn
intestine is not clear. Since neoplastic tissues
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FIGURE 2. Perinatal development of (0) UDPGT and (e) PG
in guinea pig liver. Each litter was pooled and each point
represents the mean ofthree separate litters.
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FIGURE 3. Perinatal development of (0) UDPGT and (-) PG
in guinea pig lung. Each litter was pooled and each point
represents the mean ofthree separate litters.
often exhibit enzyme profiles similar to fetal
tissues (30) it would be of interest to determine if
fG isozymes are good biochemical markers for in-
testinal carcinogenesis. Intestinal UDPGT, like
the lung enzyme, did not develop until birth and
gradually attained adult levels by 3 weeks after
birth. Deglucuronidation exceeded glucruonida-
tion at all developmental stages; the difference
being 1.5-fold in adults and greater than 500-fold
in fetal intestine.
Kidney PG remained relatively constant
throughout development; approximately 3
nmole/min/mg protein. In contrast, UDPGT was
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FIGURE 4. Perinatal development of (0) UDPGT and (e) PG
in guinea pig intestine. Each litter was pooled and each point
represents the mean ofthree separate litters.
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FIGURE 5. Perinatal development of (0) UDPGT and (-) PG
in guinea pig kidney. Each litter was pooled and each point
represents the mean ofthree separate litters.
not detectable until 2 days prior to birth and in-
creased rapidly until 2 weeks after birth, when
adult levels were attained. Deglucuronidation ex-
ceeded glucuronidation at all fetal stages and for
the first week after birth. UDPGT specific activi-
ty was sevenfold greater than PG in adult ani-
mals. Placental PG levels were high throughout
gestation although activities decreased near
term. The highest PG specific activity observed
was 23 nmole/min/mg protein at day 50 of gesta-
tion. Placental UDPGT activities were low during
gestation and nondetectable near term. In gener-
al, deglucuronidation exceeded glucuronidation
by approximately 10-fold.
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FIGURE 6. Fetal development of (0) UDPGT and (e) PG in
guinea pig placenta. Each litter was pooled and each point
represents the mean ofthree separate litters.
These results clearly illustrate the large varia-
tions in relative activities of UDPGT and fG, de-
pending on tissue and developmental stage. Of
particular note was the general predominance of
PG in fetal tissues. Although these types of stud-
ies are complicated by many factors, indications
are that net glucuronidation rates will be general-
ly low in fetal tissues. Since glucuronidation is
considered a detoxication process, the relative ac-
tivities may be partially responsible for the fetal
susceptbility to some foreign chemicals. Of
course, the role of UDPGT and PG in the activita-
tion of carcinogenic amines (31) also emphasizes
the need to quantify both these enzymes in specif-
ic tissues. Fetal clearance of glucuronides should
be relatively slow compared to maternal excre-
tion due to the lack of placental permeability to
conjugates although the retrograde transfer of
chemicals is poorly understood. For example,
following IV administration of 3H-diethyl-
stilbestrol (DES) to pregnant mice, DES-glu-
curonide concentrations in fetal plasma were
twice that ofmaternal plasma (32).
Perinatal Induction of Glucuronyltransferase
After establishing the perinatal developmental
patterns, the next step was to determine if the
patterns could be altered. The chemical that
we selected, 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), is an extremely toxic contaminant of
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the herbicide 2,4,5-trichlorophenoxyacetic acid
(33). The oral LDso ranges from 1 Ag/kg in guinea
pigs to 100 ,ug/kg in rats. We have also shown
that TCDD is an extremely potent and persistent
inducer of some microsomal enzymes in rats; ap-
proximately 50000 times more potent than the
classic including agent phenobarbital (Table 1,
Fig. 7) (6). Induction is apparently caused by an
increase in enzyme systheses as evidenced by ki-
netic data, UDPGT solubilization and partial pur-
ification studies, and the prevention of induction
by actinomycin D (7).
TCDD, after administration to pregnant rats
on day 5 of gestation, did not affect fetal glu-
curonidation rates of PNP (Fig. 8). However, a
marked postnatal inductive effect was observed.
The increase was twofold 1 week after birth, and
maximum induction (eightfold) occurred 3 weeks
after birth. UDPGT activity 52 days after birth
was still increased twofold. The developmental
patterns were similar when pregnant rats were
administered TCDD on the days 5, 10, or 16 of
gestation. TCDD effects were also similar when
PNP, 1-naphthol, or methylumbelliferone were
used as substrates. Postnatal induction was evi-
dent in extrahepatic as well as hepatic tissues
(Table 2) and occurred for hydroxylation reac-
tions (8).
The postnatal inductive effect must have re-
sulted either from newborn exposure to TCDD in
milk or to the activation of an inducing mecha-
nism about the time of birth. Data from cross-
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FIGURE 7. Time course effects of a single oral dose of TCDD
on male rat liver UDPGT: (0) controls; (0) 5 jHg TCDD/kg;
(.) 25 ,ug TCDD/kg. N=3 rats. An asterisk indicates that
values are significantly different from controls at least at p<
0.05.
Table 1. Change in activities of female rat liver microsomal
enzymes following a single oral dose ofTCDD.'
Relative change from control
values (l00)1
TCDD, TCDD, TCDD, TCDD,
0.05 0.2 1.0 5.0
Enzyme ,ug/kg jg/kg jAg/kg jAg/kg
Cytochrome P-450 - 126' 153C 196C
Benzphetamine de-
methylation - 115 112 118
Benzpyrene hydrox-
ylation 351c 783C 1225X 1403'
Glucuronyltransferase 142c 257C 506C 687C
aRats were killed 3 days after TCDD treatment at various
dose levels. Each value derived from four animals.
bData calculated on the basis ofspecific activities.
c Significantly different from controls at least atp< 0.05.
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FIGURE 8. Effects of oral TCDD treatment (3 jg/kg) of preg-
nant rats on the development of hepatic fetal and newborn
PNP glucuronidation: (0) control; (e) TCDD. Each litter
was pooled and each point represents the average of three
separate litters.
Table 2. Postnatal induction ofhepatic and extrahepatic
glucuronyltransferase by TCDDin rats.'
PNP conjugated,
nmole/min/mg protein Induction
factor
Tissue Control TCDD
Liver 27.3 159.4 5.8
Lung 0.3 2.9 9.7
Kidney 8.4 87.7 10.4
Intestine 1.2 15.5 12.9
Testes 6.6 7.0 1.1
a Rats treated (3 Mg/kg) on day 15 of gestation and sacrificed
8days after birth.
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cate that exposure of newborns to milk contain-
ing TCDD was the primary factor. Secretion of
TCDD in milk appears to be an extremely effi-
cient excretory system, since maternal induction
levels decreased sharply postpartum after gasta-
tional TCDD treatment (Fig. 9). If pups were re-
moved from TCDD-treated mothers immediately
after birth, preventing suckling, the maternal in-
duction decay curve was less rapid. Induction
levels in fetal and newborn tissues correlated
well with tissue distribution experiments follow-
ing treatment of pregnant rats with `4C-TCDD on
the day 11 of gestation (J. Moore, NIEHS, un-
published observations). One day prior to birth,
each fetus had received a dose of 0.3 jg/kg,
whereas 14 days after birth the dose was 1.8
Mig/kg. Each fetus received approximately 1.0 ng
TCDD by the day prior to birth, compared to 40
ng 14 days after birth.
Table 3. Postnatal induction of hepatic microsomal enzymes
by TCDD treatment 13 Mg/kg) of pregnant rats following
cross-fostering ofcontrol and TCDD-treated groups."
Benzpyrene hydrox-
PNP glucuronidation ylation, nmole 3-
nmole/min/mg hydroxybenzpyrene/min/
Animalsb microsomal protein mgmicrosomal protein
Group 1 18.6 ± 1.5 0.227 +0.016
Group 2 99.5 ± 6.4c 1.115 ±0.083c
Group 3 100.4 ± 8.9c 1.143 +0.091c
Group 4 33.3 ± 2.4c 0.604 ±0.073c
Group 5 95.6 +12.3c 0.604 +0.073c
' Pregnant rats were treated on the day 5 of gestation, and
the newborns were sacrificed 8days after birth.
I Group 1, control mothers nursing control pups; group 2,
TCDD-treated mothers nursing TCDD-treated pups; group 3,
TCDD-treated mothers nursing control pups; group 4, control
mothers nursing prenatally TCDD-treated pups; group 5,
mother rats administered TCDD immediately after giving
birth.
Significantly different from group 1,p<O.Ol.
UDPGT Multiplicity
Considerable research has been documented
recently to demonstrate the enzyme multiplicity
of glucuronyltransferase (7,8 17-19). Research in
our laboratories has provided evidence that peri-
natal developmental patterns of steroid glu-
curonidations differ significantly from nonsteroid
pathways (8). Steroid substrates used in these
studies were testosterone, P-estradiol, and
estrone.
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FIGURE 9. Effects of oral TCDD treatment (3 ,ug/kg) of preg-
nant rats on the time course of maternal hepatic UDPGT ac-
tivities: (0) control; (.) TCDD. Each point represents three
animals.
The normal developmental patterns of steroid
glucuronidations in control and TCDD- treated
rats are illustrated in Figure 10. The perinatal
patterns differed from nonsteroid glucuronida-
tions in two ways: (1) there was no developmental
peak in enzyme activity at birth such that glu-
curonidation rates at birth exceeded adult ac-
tivities; and (2) TCDD did not cause postnatal in-
duction of steroid glucuronidations. P-Estradiol
has two sites for glucuronidation: at the 3-OH and
17-OH positions. The perinatal patterns at both
sites were similar, and neither was TCDD-
inducible. A third differentiating factor involves
tissue distributions of steroid and nonsteroid UD-
PGT. Nonsteroid glucuronidation enzymes have
relatively high activities in male and female
reproductive tract tissue, whereas steroid UD-
PGT is low or nondetectable (34). A summary of
steroid and nonsteroid substrates is presented in
Table 4. Phenolphthalein, which has estrogenic
activity, was glucuronidated as a steroid.
The synthetic estrogen, diethylstilbestrol
(DES), has potent steroidal properties as well as
being a foreign chemical. DES has been used as a
gynecological treatment and cattle food additive
and has recently received considerable attention
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FIGURE 10. Effects of oral TCDD treatment (3 pg/kg) of preg-
nant rats on the development of hepatic fetal and newborn
P-estradiol glucuronidation: (0) control; (-) TCDD. Each lit-
ter was pooled and each point represents the average of
three separate litters.
Table 4. Summary of glucuronidation characteristics of some
steroid and nonsteroid substrates.-
Develop- Reproductive
mental TCDD tract
Substrate peak induction activity
p-Nitrophenol + + + + + + + + +
1-Naphthol + + + + + + + + +
4-Methylumbel-
liferone + + + + + + + + +
Testosterone - - -
Estradiol - +
Estrone -
Diethylstilbestrol - + +
Phenolphthalein -
a +++ denotes pronounced effect; + indicates slight effect; -
indicates lack of effect or activity.
because of its implication as a transplacental car-
cinogen (35,36). It also appears that DES causes
deficits in reproductive tract function and altered
morphology in offspring following gestational ex-
posures. Our studies were directed initially to
determine whether DES is glucuronidated as a
steroid or nonsteroid. The major metabolic path-
way for DES is glucuronidation (37), although
some nonpolar metabolites have been identified
(38). The perinatal development in rats is il-
lustrated on Figure 11; the data clearly indicate
that DES is glucuronidated as a steroid.
oBirth 0
8-.
v6-
0C
- 2i
c 18 22' +4 +12 +20 +28
GestationalI period or age
(rcats treated on 5th'dayofgestartion)
FIGURE 11. Effects of oral TCDD treatment (3 ,ug/kg) of preg-
nant rates on the development of hepatic fetal and newborn
DES glucuronidation: (O) control; (-) TCDD. Each litter
was pooled and each point represents the average of three
separate litters.
Influence of UDPGT on Perinatal Pharmacology
Perinatal developmental patterns, alone, have
limited value. Therefore, we performed experi-
ments to determine if the perinatal develop-
mental pattern of DES UDPGT correlated with
fetal levels of DES-glucuronide following 3H-DES
administration to pregnant mice atvarying gesta-
tional ages. Mice were used in these studies
rather than rats because of the availability of a
well-defined mouse model for DES-induced
transplacental carcinogenesis (36). It is unlikely
that significant quantities of DES-glucuronide
formed in the maternal compartment would cross
the placenta. Therefore it is reasonable to assume
that DES-glucuronide detected in the fetus was
formed in the fetal compartment. Results (Table
5) indicate that during the earlier gestational
ages, when DES UDPGT activities are low or un-
detectable, only small amounts of 3H-DES
glucuronide were present in fetal tissues. As
hepatic DES UDPGT activities increased during
development, fetal levels of 3H-DES glucuronide
increased concommitantly. It is also interesting
to note that, although 3H-DES glucuronide con-
centrations increased with gestational age, fetal
Environmental Health Perspectives 32Table 5. Fetal levels ofDESand its conjugates.
UDPGT activity
Conjugates, in fetal liver,
Day of DES, ng/g DES ng/g nmde/DES glu-
gestation fetus ab fetus a b curonide/min/
mgmicrosomal
protein
11 1.10 ± 0.05 0.10 ± 0.02 -
12 1.13 ± 0.07 0.21 ± 0.02 -
14 1.47 ± 0.10 0.55 ± 0.07 0.17 ± .004
16 1.20 ± 0.10 1.74 ± 0.20 4.80 ± 0.24
aConcentration of DES and its conjugates in whole fetuses
30 min after IV administration of tritiated DES (30 pg/kg).
Each value represents mean ± S.E. ofobservations in 3 mice.
b Each value represents mean ± S.E. of observations in 4
mice. Fetal livers from the same litter were pooled.
concentrations of DES remained relatively con-
stant. Therefore, there were significantly greater
fetal concentrations of radioactivity at the later
stages compared to the earlier. This finding
might have toxicological significance, in that
DES-glucuronide should not be readily cleared
from the fetal compartment and DES could be
liberated from the fetal DES-glucuronide pool
by/3G. DES was identified by Florisil chroma-
tography and three thin-layer systems. Approx-
imately 5% of the recovered radioactivity re-
sided in unidentified nonpolar methabolites (32).
In a recent report (38), several nonpolar metabo-
lites of DES were identified in mammals, includ-
ing dienstrol, hydroxyl, and methylated deriva-
tives. It is possible that some of the unidentified
compounds in mice (32) could be these metabo-
lites. Metzler et al. (38) postulate that the
dienstrol metabolites might be formed through
an epoxide intermediate. It is concluded that the
perinatal development ofUDPGT plays an impor-
tant role in the pharmacology and perhaps toxici-
ty of many foreign chemicals. This enzyme sys-
tem appears also to function in the metabolic
regulation of steroid hormones during develop-
ment and is sensitive to chemical insult in new-
born as well as adult animals.
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